anaplastic astrocytoma (Cancer)
Information
- Disease name
- anaplastic astrocytoma
- Disease ID
- DOID:3078
- Description
- "A malignant astrocytoma that is characterized by cells with regular, round to oval nuclei." [url:http\://en.wikipedia.org/wiki/Anaplastic_astrocytoma, url:http\://www.cancer.gov/dictionary?CdrID=45591]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| IDH2 | 15 | 90,083,045 | 90,102,468 | 4 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05934630 | Active, not recruiting | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors | July 12, 2023 | July 12, 2028 | |
| NCT02101905 | Active, not recruiting | Phase 1 | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | March 13, 2014 | October 19, 2024 |
| NCT03180502 | Active, not recruiting | Phase 2 | Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma | August 2, 2017 | January 2030 |
| NCT03581292 | Active, not recruiting | Phase 2 | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | November 6, 2018 | September 22, 2024 |
| NCT03561207 | Active, not recruiting | 3D Prediction of Patient-Specific Response | June 11, 2018 | December 2024 | |
| NCT01204684 | Active, not recruiting | Phase 2 | Dendritic Cell Vaccine for Patients With Brain Tumors | October 8, 2010 | January 31, 2026 |
| NCT04295759 | Active, not recruiting | Phase 1 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | July 27, 2020 | June 30, 2024 |
| NCT00089427 | Completed | Phase 1 | IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma | July 2004 | |
| NCT00100802 | Completed | Phase 2 | Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas | March 21, 2005 | June 30, 2017 |
| NCT00115440 | Completed | Phase 1/Phase 2 | BNCT to Treat Glioma That Has Progressed Following Radiotherapy | March 2001 | January 2009 |
| NCT00301418 | Completed | Phase 1/Phase 2 | Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma | March 2006 | May 2014 |
| NCT00390299 | Completed | Phase 1 | Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | October 23, 2006 | November 30, 2019 |
| NCT00409214 | Completed | Phase 2 | Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma | November 2006 | |
| NCT00430911 | Completed | Phase 3 | Radiotherapy for Malignant Astrocytomas in the Elderly | February 2001 | |
| NCT00431561 | Completed | Phase 2 | Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma | April 2003 | March 2009 |
| NCT00589875 | Completed | Phase 2 | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | March 2007 | August 2016 |
| NCT00606008 | Completed | Phase 2 | A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma | March 2007 | August 2012 |
| NCT00610571 | Completed | Phase 1 | Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | April 2004 | April 2012 |
| NCT00612651 | Completed | Phase 1 | PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas | October 2005 | June 2011 |
| NCT00667394 | Completed | Phase 2 | Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors | April 2008 | July 2011 |
| NCT00717210 | Completed | Phase 3 | Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide | June 1999 | March 2008 |
| NCT00734682 | Completed | Phase 1 | A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas | August 2008 | December 2014 |
| NCT00751270 | Completed | Phase 1 | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | November 2005 | January 2011 |
| NCT00003470 | Completed | Phase 2 | Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma | March 1996 | December 2009 |
| NCT00004688 | Completed | Phase 2 | Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms | August 1996 | July 1998 |
| NCT00024557 | Completed | Phase 1 | Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients | June 2001 | July 2007 |
| NCT00024570 | Completed | Phase 1/Phase 2 | Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma | November 2000 | July 2007 |
| NCT00031083 | Completed | Phase 1 | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | April 2, 2002 | October 10, 2003 |
| NCT00041587 | Completed | Phase 1/Phase 2 | Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma | July 2002 | July 2007 |
| NCT00064779 | Completed | Phase 1 | Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma | July 2003 | July 2007 |
| NCT00879437 | Completed | Phase 2 | Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma | September 1, 2009 | October 2, 2017 |
| NCT00884416 | Completed | Phase 1 | Sorafenib in Newly Diagnosed High Grade Glioma | March 2009 | March 2012 |
| NCT00968240 | Completed | Phase 1 | Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) | July 2009 | January 2014 |
| NCT00995007 | Completed | Phase 2 | A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas | September 2009 | December 2015 |
| NCT01082926 | Completed | Phase 1 | Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 | May 2010 | September 2013 |
| NCT01144247 | Completed | Phase 1 | Cellular Immunotherapy Study for Brain Cancer | July 2010 | July 2015 |
| NCT01151670 | Completed | Phase 1 | Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors | August 2010 | August 2014 |
| NCT01156584 | Completed | Phase 1 | A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma | July 2010 | August 18, 2016 |
| NCT01171469 | Completed | Phase 1 | Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | September 2010 | June 2012 |
| NCT01180816 | Completed | Phase 1 | Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA | August 2010 | August 11, 2020 |
| NCT01189266 | Completed | Phase 1/Phase 2 | Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma | August 9, 2010 | September 30, 2021 |
| NCT01222754 | Completed | Phase 1 | Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas | November 23, 2010 | April 17, 2019 |
| NCT01238237 | Completed | Phase 1 | Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA | December 2009 | January 2016 |
| NCT01250470 | Completed | Phase 1 | Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma | September 5, 2012 | May 29, 2014 |
| NCT01316809 | Completed | Phase 1 | AZD8055 for Adults With Recurrent Gliomas | March 4, 2011 | April 4, 2016 |
| NCT01380782 | Completed | Phase 2 | BIBF 1120 for Recurrent High-Grade Gliomas | May 2012 | July 2014 |
| NCT01470794 | Completed | Phase 1 | Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor | February 2012 | April 12, 2016 |
| NCT01502241 | Completed | Phase 3 | Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly | January 2005 | November 2011 |
| NCT01514201 | Completed | Phase 1/Phase 2 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | February 1, 2012 | March 28, 2018 |
| NCT01522820 | Completed | Phase 1 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | March 2012 | July 2016 |
| NCT01808820 | Completed | Phase 1 | Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | August 21, 2013 | July 16, 2022 |
| NCT01922076 | Completed | Phase 1 | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | September 3, 2013 | September 30, 2022 |
| NCT01967758 | Completed | Phase 1 | Phase I Study of Safety and Immunogenicity of ADU-623 | January 8, 2014 | August 15, 2018 |
| NCT01975116 | Completed | Phase 1 | p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors | August 2013 | April 2015 |
| NCT01985256 | Completed | Phase 1 | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor | February 2014 | March 3, 2016 |
| NCT02022384 | Completed | Immunophenotyping From Blood of Patients With Malignant Gliomas | December 2013 | December 31, 2022 | |
| NCT02238496 | Completed | Phase 1 | Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | December 8, 2014 | February 14, 2021 |
| NCT02457845 | Completed | Phase 1 | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | May 2016 | January 2024 |
| NCT02490930 | Completed | Early Phase 1 | A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma | July 2015 | September 2017 |
| NCT02644291 | Completed | Phase 1 | Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | May 2016 | June 9, 2022 |
| NCT02684058 | Completed | Phase 2 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | December 28, 2017 | April 28, 2023 |
| NCT03043391 | Completed | Phase 1 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | November 7, 2017 | March 23, 2022 |
| NCT03072134 | Completed | Phase 1 | Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | April 24, 2017 | July 1, 2021 |
| NCT03355794 | Completed | Phase 1 | A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | November 14, 2017 | July 31, 2022 |
| NCT03434262 | Completed | Phase 1 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | March 5, 2018 | May 24, 2024 |
| NCT05039346 | Completed | Quality of Life and Patient Needs in Advanced High Grade Gliomas | February 11, 2012 | January 30, 2023 | |
| NCT02755987 | No longer available | Expanded Access to ANG1005 for Individual Patients | |||
| NCT06333899 | Not yet recruiting | Early Phase 1 | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | September 1, 2024 | September 1, 2034 |
| NCT06241391 | Not yet recruiting | N/A | Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas | February 2024 | February 2025 |
| NCT05839379 | Not yet recruiting | Targeted Pediatric High-Grade Glioma Therapy | May 30, 2024 | May 30, 2034 | |
| NCT05843253 | Not yet recruiting | Phase 2 | Study of Ribociclib and Everolimus in HGG and DIPG | May 30, 2024 | May 30, 2034 |
| NCT03975829 | Recruiting | Phase 4 | Pediatric Long-Term Follow-up and Rollover Study | November 4, 2019 | May 29, 2026 |
| NCT06264388 | Recruiting | Phase 2 | DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | May 1, 2024 | May 1, 2034 |
| NCT01269853 | Recruiting | Phase 1/Phase 2 | Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | October 2010 | October 2026 |
| NCT05698524 | Recruiting | Phase 1 | A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma | June 26, 2023 | June 2027 |
| NCT03603405 | Recruiting | Phase 1/Phase 2 | HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM | February 28, 2018 | December 31, 2025 |
| NCT03919071 | Recruiting | Phase 2 | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | February 20, 2020 | September 30, 2027 |
| NCT01837862 | Recruiting | Phase 1/Phase 2 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | October 22, 2013 | April 2025 |
| NCT04541082 | Recruiting | Phase 1 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | October 26, 2020 | February 2025 |
| NCT05084430 | Recruiting | Phase 1/Phase 2 | Study of Pembrolizumab and M032 (NSC 733972) | February 25, 2022 | March 1, 2028 |
| NCT02800486 | Recruiting | Phase 2 | Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA | May 2016 | May 2026 |
| NCT05956821 | Recruiting | Phase 1/Phase 2 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | August 1, 2024 | December 1, 2029 |
| NCT06108206 | Recruiting | N/A | Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma | January 30, 2024 | December 31, 2026 |
| NCT05099003 | Recruiting | Phase 1/Phase 2 | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | May 31, 2022 | June 30, 2027 |
| NCT02372409 | Recruiting | Phase 2 | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors | August 14, 2015 | August 31, 2030 |
| NCT04978727 | Recruiting | Phase 1 | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | July 1, 2022 | June 30, 2028 |
| NCT04780009 | Recruiting | Loupe-Based Intraoperative Fluorescence Imaging | November 17, 2017 | August 2024 | |
| NCT01849952 | Recruiting | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas | February 28, 2020 | May 2024 | |
| NCT04047264 | Recruiting | N/A | Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies | January 1, 2020 | September 1, 2027 |
| NCT01386710 | Suspended | Phase 1/Phase 2 | Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma | September 2011 | December 2026 |
| NCT03973918 | Terminated | Phase 2 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG | July 29, 2019 | October 1, 2023 |
| NCT01884740 | Terminated | Phase 1/Phase 2 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | June 2013 | October 2018 |
| NCT04608812 | Terminated | Phase 1 | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection | March 2, 2021 | February 27, 2023 |
| NCT02039778 | Terminated | N/A | Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma | December 2013 | December 2015 |
| NCT02168270 | Terminated | Phase 1 | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | June 16, 2014 | August 20, 2015 |
| NCT02414165 | Terminated | Phase 2/Phase 3 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma | November 30, 2015 | December 20, 2019 |
| NCT00031538 | Terminated | Genetic Analysis of Brain Tumors | March 1, 2002 | April 29, 2015 | |
| NCT02758366 | Terminated | Phase 2 | Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma | February 2016 | January 16, 2020 |
| NCT00761280 | Terminated | Phase 3 | Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma | December 2008 | June 2012 |
| NCT02885324 | Terminated | Phase 2 | Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children | May 18, 2017 | August 25, 2020 |
| NCT01095094 | Terminated | Phase 2 | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | January 2009 | November 2011 |
| NCT00473408 | Terminated | The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas | March 2007 | November 2011 | |
| NCT03332355 | Terminated | Phase 1 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 | October 1, 2017 | December 31, 2021 |
| NCT00062504 | Terminated | Phase 2 | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | July 2003 | April 2006 |
| NCT01227434 | Terminated | Phase 2 | A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma | September 2010 | December 2013 |
| NCT01281982 | Terminated | (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas | January 13, 2011 | September 24, 2012 | |
| NCT03971734 | Terminated | Phase 1 | Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas | December 6, 2019 | October 2, 2023 |
| NCT00035373 | Terminated | Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols | April 19, 2002 | April 29, 2015 | |
| NCT01721577 | Terminated | Phase 1/Phase 2 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas | December 2012 | December 2015 |
| NCT01836549 | Terminated | Phase 2 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | March 2013 | April 2016 |
| NCT03370926 | Unknown status | FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy | October 31, 2016 | October 31, 2019 | |
| NCT02796261 | Unknown status | Phase 3 | Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients | July 2016 | June 2023 |
| NCT01637753 | Unknown status | N/A | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma | June 2012 | December 2013 |
| NCT01656980 | Unknown status | Phase 3 | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma | August 2012 | December 2014 |
| NCT01765088 | Unknown status | Phase 3 | A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas | September 2012 | December 2019 |
| NCT02629757 | Unknown status | Phase 3 | A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas | April 2015 | May 2023 |
| NCT00114309 | Unknown status | Phase 2 | 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma | November 2004 | August 2009 |
| NCT02540135 | Withdrawn | N/A | Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma | March 1, 2015 | July 18, 2018 |
| NCT04105374 | Withdrawn | Phase 2/Phase 3 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | January 31, 2020 | November 30, 2030 |
| NCT00645385 | Withdrawn | Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme. | June 2007 | June 1, 2011 | |
| NCT00734864 | Withdrawn | Phase 1 | Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | June 2009 | June 2012 |
| NCT01861990 | Withdrawn | Phase 1 | Valproic Acid in Childhood Progressive Brain Tumors | May 2013 | December 2013 |
| NCT01711580 | Withdrawn | Re-irradiation of High Grade Gliomas: a Quality of Life Study | March 2013 | September 2015 |
- Disase is a (Disease Ontology)
- DOID:3069
- Cross Reference ID (Disease Ontology)
- GARD:5860
- Cross Reference ID (Disease Ontology)
- MESH:D001254
- Cross Reference ID (Disease Ontology)
- NCI:C9477
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:55353007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0334579
- Exact Synonym (Disease Ontology)
- grade III Astrocytic tumor
- Exact Synonym (Disease Ontology)
- grade III astrocytoma
- OrphaNumber from OrphaNet (Orphanet)
- 251589